Technology
Lucid Diagnostics Q4 Revenues Rise 20 Percent
The firm's full-year 2024 revenues increased 79 percent year over year to $4.3 million.
The test can be used to better stratify cancer patients and determine the likelihood of breast cancer metastasizing.
Public health labs have handled most testing thus far for the Texas and New Mexico outbreaks, but commercial labs are beginning to bring molecular measles assays online.
The firm has multiple infectious disease tests in its pipeline and is currently in initial conversations with potential investors and partners.
Leaders from diagnostics firms and academia discussed the challenges of assessing these tests and the need for a consensus on how to bring them to the clinic.
Mar 19, 2025
Mar 14, 2025
Mar 11, 2025